Role of pregablin in neuropathic pain

ABSTRACT

To evaluate the role of pregablin in neuropathic pain. Prospective descriptive study. This study was conducted in the department of medicine of Al-Tibri Medical College and Hospital from Jan. 2011 to Jan 2012. A prospective study conducted in a private hospital of Karachi from Jan 2011 to Jan 2012. A total 107 cases were enrolled. All patients are adult above 18 years of age. The neuropathic pain was analyzed by Leeds Assessment of Neuropathic symptoms and sign [LANSS]. The pain was assessed by numeric pain rating scale. The data was recorded on a preset performa. Primary disease was also controlled and all the patients were given pregablin 50-150mg/day for two-six weeks. The symptoms were re assess by numeric pain scale. The SPSS 16 used to analysed. Total number of patients were 107. Male were 52 while female were 55. The patients were grouped according to pathology. The most common pathology was Diabetes in 49 cases [45.79%] followed by hypertension in 35 cases [32.71%] and herpes zoster in 27 cases [25.23%]. The age ranges from 42-72 years with mean age is 56.66 +/- 16. The dose ranges from 50-150 mg per day and the duration of treatment were two- six weeks. The pregablin was superior in relieving pain and sleep in patient with diabetic neuropathy and post herpetic neuralgias. The adverse effects noted were somnolence, lethargy and ataxia. Two of the cases were stopped treatment due to somnolence. The result of adding pregablin in the treatment of a patient with neuropathic pain was very successful and it is improving the quality of life and sleep